Autonomix Medical Files 10-Q for Q3 2025

TL;DR

**Autonomix Medical 10-Q filed! Check financials for Q3 2025.**

AI Summary

Autonomix Medical, Inc. filed a 10-Q for the period ending December 31, 2024. The company reported a fiscal year end of March 31st and is incorporated in Delaware. Key financial figures and business addresses in The Woodlands, TX were disclosed.

Why It Matters

This filing provides a quarterly update on Autonomix Medical's financial health and operational status, crucial for investors assessing the company's performance.

Risk Assessment

Risk Level: medium — The filing contains financial data and business updates, but lacks specific forward-looking statements or major event disclosures that would indicate high risk.

Key Numbers

• 500,000,000 — Authorized Shares (Indicates the total number of shares the company is permitted to issue.)
• 2,462,983 — Outstanding Shares (Represents the number of shares currently held by investors.)
• 942,575 — Treasury Shares (Shares repurchased by the company, reducing the number of outstanding shares.)
• 19.93% — Discount Rate (Used in fair value measurements as of December 31, 2023, reflecting the company's cost of capital or risk assessment.)

Key Players & Entities

• Autonomix Medical, Inc. (company) — Filer of the 10-Q
• 21 WATERWAY AVENUE, SUITE 300 (location) — Business and Mail Address
• The Woodlands, TX (location) — City and State of Business Address
• December 31, 2024 (date) — End of reporting period
• March 31 (date) — Fiscal year end

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value AMIX The Nasdaq Stock Mar
• $250 thousand — xcess of the federally insured limit of $250 thousand. The Company has not experienced losses

Filing Documents

• amix20241231_10q.htm (10-Q) — 1094KB
• ex_746086.htm (EX-31.1) — 11KB
• ex_746087.htm (EX-31.2) — 11KB
• ex_746088.htm (EX-32.1) — 5KB
• ex_746089.htm (EX-32.2) — 5KB
• logo.jpg (GRAPHIC) — 7KB
• 0001437749-25-003669.txt ( ) — 6532KB
• amix-20241231.xsd (EX-101.SCH) — 55KB
• amix-20241231_cal.xml (EX-101.CAL) — 22KB
• amix-20241231_def.xml (EX-101.DEF) — 453KB
• amix-20241231_lab.xml (EX-101.LAB) — 369KB
• amix-20241231_pre.xml (EX-101.PRE) — 470KB
• amix20241231_10q_htm.xml (XML) — 1049KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 4 Unaudited Condensed Balance Sheets as of December 31, 2024 and March 31, 2024 4 Unaudited Condensed Statement of Operations for the three and nine months ended December 31, 2024 and 2023 5 Unaudited Condensed Statements of Stockholders ' Equity for the three and nine months ended December 31, 2024 and 2023 6 Unaudited Condensed Statement of Cash Flows for the nine months ended December 31, 2024 and 2023 7 Notes to the Unaudited Condensed Financial Statements 8 Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 24 Item 4.

Controls and Procedures

Controls and Procedures 24

OTHER INFORMATION

PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 26 Item 1A.

Risk Factors

Risk Factors 26 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 26 Item 3. Defaults Upon Senior Securities 26 Item 4. Mine Safety Disclosures 26 Item 5. Other Information 26 Item 6. Exhibits 26

Signatures

Signatures 27 3 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Autonomix Medical, Inc. Condensed Balance Sheets (Unaudited) (in thousands, except par value and share data) As of December 31, March 31, 2024 2024 Assets Current assets: Cash and cash equivalents $ 11,823 $ 8,608 Other current assets 109 783 Total current assets 11,932 9,391 Long term assets: Fixed assets, net 20 16 Total long term assets 20 16 Total Assets $ 11,952 $ 9,407 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 232 $ 492 Short term debt - convertible notes, net of unamortized debt discount 1,132 - Accrued expenses 881 285 Total current liabilities 2,245 777 Long term liabilities: Long term debt - convertible notes, net of unamortized debt discount - 1,002 Total long term liabilities - 1,002 Total Liabilities $ 2,245 $ 1,779 Commitments and contingencies (Note 5) Stockholders' equity: Preferred stock, $ 0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2024 and March 31, 2024, respectively $ - $ - Common stock, $ 0.001 par value, 500,000,000 shares authorized, 2,462,983 and 942,575 shares issued and outstanding as of December 31, 2024 and March 31, 2024, respectively 2 1 Additional paid-in capital 56,892 46,596 Accumulated deficit ( 47,187 ) ( 38,969 ) Total Stockholders' Equity 9,707 7,628 Total Liabilities and Stockholders' Equity $ 11,952 $ 9,407 See accompanying notes to the unaudited condensed financial statements. 4 Table of Contents Autonomix Medical, Inc. Condensed Statements of Operations (Unaudited) Three Months Ended Nine Months Ended December 31, December 31, 2023 2023 (in thousands, except share and per share data) 2024 (as revised) 2024 (as revised) Operating expenses: General and administrative $ 1,703 $ 2,237 $ 5,164 $ 3,531 Research and development 1,044 687 3,172 1,527 Warrant expense - termination agree

View Full Filing

View this 10-Q filing on SEC EDGAR